- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05318326
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
19. april 2022 opdateret af: Chengdu Easton Biopharmaceuticals Co,Ltd
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets in Chinese Patients With Type 2 Diabetes Mellitus and Poor Diet and Exercise Control
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient glycaemic control with diet and exercise.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The treatment period is composed of a 24-week double-blind period (week 1-24) and a 28-week open-label period (week 25-52).
During the double-blind period, participants will receive 200 mg or 400 mg dose of Yogliptin and matching placebo, or placebo only.
During the open-label period, all participants will receive 400 mg dose of Yogliptin.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
450
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: yunju Yi
- Telefonnummer: +8613518115493
- E-mail: yiyunju@eastonpharma.cn
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina
- Rekruttering
- Beijing Hospital
-
Kontakt:
- Lixin Guo
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- 1.Men or women aged 18 to 75 years old at the day of signing the informed consent;
- 2.Type 2 diabetes patients who meet the diagnostic criteria for diabetes issued byChinese Guidelines for the Prevention and Treatment of Type 2 Diabetesin 2020;
- 3.Receive at least 8 weeks of diet and exercise treatment before screening;Not treated with any antidiabetic drugs within 8 weeks before screening;
4.Glycated hemoglobin (HbA1c): Screening period: HbA1c 7.5% to 11% (tested by the research center), when randomly enrolled: HbA1c 7.0% to 10.5% (central laboratory test) Measurement);
5.fasting blood glucose(FPG): Screening period: FPG≤15.0mmol/L (tested by the research center), when randomly enrolled: FPG≤15.0mmol/L (central laboratory test) Measurement);
- 6.Screening period Body mass index(BMI) 19.0kg/m2 to 35.0kg/m2 ;
- 7.Agree to maintain the same diet and exercise habits throughout the trial and be willing and able to accurately use a home blood glucose meter for self-monitoring and recording of blood glucose
- 8.Can understand the procedures and methods of this study, willing to strictly abide by the clinical trial protocol to complete this trial, and voluntarily sign an informed consent.
Exclusion Criteria:
- 1.Non-type 2 diabetes: such as type 1 diabetes, secondary diabetes or other special types of diabetes ;
- 2.History or condition of any of the following at screening or run-in:Those who have a history of diabetic ketoacidosis, hyperglycemia and hyperosmolarity, lactic acidosis and other acute complications of diabetes within 6 months before screening;
- 3.History or condition of any of the following at screening or run-in:Unstable condition or severe diabetic complications such as proliferative retinopathy or maculopathy, severe diabetic neuropathy, intermittent claudication, diabetic foot in the past 6 months;
- 4.History or condition of any of the following at screening or run-in:Three or more episodes of grade 3 hypoglycemia in the past 6 months (according to the diagnostic criteria for hypoglycemia in the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition)) ;
- 5.History or condition of any of the following at screening or run-in:Unstable angina, stroke or transient ischemic attack, myocardial infarction, coronary artery bypass graft or percutaneous coronary intervention (diagnostic angiography is allowed of);
- 6.History or condition of any of the following at screening or run-in:Hemorrhagic stroke or ischemic stroke within the past 6 months, and is not suitable for this clinical trial judged by the investigator ;
- 7. History or condition of any of the following at screening or run-in:Previous history of other serious endocrine diseases affecting glucose metabolism, such as multiple endocrine neoplasia, limb hypertrophy syndrome, Cushing's syndrome, etc., which are not suitable for this clinical trial judged by the ;
- 8. History or condition of any of the following at screening or run-in:Patients with previous severe digestive system diseases, nutritional metabolic diseases and rheumatic diseases, who are not suitable to participate in this clinical trial as judged by the investigator;
- 9. any of the following medical history or conditions at screening or run-in: current thyroid dysfunction not controlled with stable drug dose, and clinically significant abnormalities in thyroid function test results at screening
- 10 Any of the following medical history or conditions at screening or run-in: History or presence of malignancy (except for malignancies that have not recurred in the last 5 years)
- 11 History or condition of any of the following at screening or run-in: Presence of significant psychiatric disorder or speech disorder Unwilling or unable to fully understand and collaborate Contacts and Locations
- 12 Any of the following medical history or conditions at screening or run-in: significant infection or major surgery within 6 months prior to screening, which, in the judgment of the investigator, would make the patient inappropriate for this clinical trial ;
- 13 History or conditions of any of the following at screening or run-in: those with a history or clinical evidence of acute or chronic pancreatitis;
- 14 History or condition of any of the following at screening or run-in: poorly controlled blood pressure, ie, systolic blood pressure (SBP) > 160 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg ;
- 15 Use of any of the following medications or therapies prior to Screening or Run-in: Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists prior to Screening or within 3 months prior to Run-in ;
- 16 Use of any of the following drugs or therapies before screening or run-in: Use of other drugs that may affect glucose metabolism, such as systemic glucocorticoids, growth hormone, etc., before screening or within 3 months before run-in;
- 17 Use of any of the following drugs or therapies before screening or run-in: those with cumulative use of insulin and its analogues for more than 28 days in the previous year (except for gestational diabetes treated with insulin and its analogues)
- 18. When screening, any one of the laboratory inspection indicators meets the following standards: ALT/AST> 2.5ULN; Total bilirubin> 2.0ULN; Subjects with current severe renal disease, or eGFR (CKD-EPI2012Scr-CysC) ≤ 60 mL/min/1.73 m2;TG)>5.6mmol/L;Blood amylase>>1.5ULN;HGB<10.0g/dL(100g/L);
- 19 Any positive HCV antibody, HIV antibody or Treponema pallidum antibody at screening; positive hepatitis B HBsAg, additionally test hepatitis B virus load (HBV-DNA), positive HBsAg and HBV-DNA higher than the lower limit of detection in the local laboratory;
- 20 .The patient may have any contraindications, allergies or hypersensitivity to Test drug (including study drug and placebo) or its excipients, DPP4 drugs
- 21.Patients with a history of joint pain after taking DPP-4 inhibitors ;
- 22.Patients who have received 3 or more times of clinical trial drugs within the past year, or patients who have received 1 time of clinical trial drugs within 1 month before screening ;
- 23 Female subjects who are pregnant, lactating, or planning pregnancy during the study ;
- 24 Male and female subjects of childbearing potential who do not agree to practice contraception during the study. Females of childbearing potential (including those less than 2 years postmenopausal) must agree to practice a reliable method of contraception (e.g., transdermal contraceptive patch, implantable long-acting solution for injection, contraceptive ring, subdermal implant, intrauterine device, or double barrier method (diaphragm+condom) throughout the entire study period) ;
- 25 One or more grade 3 hypoglycemic events without obvious cause during the run-in period ;
- 26 Medication compliance with the lozenge was < 75% or > 125% during the run-in period ;
- 27 The subject has any other factors that the investigator considers inappropriate for the trial 。
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: Placebo kontrolgruppe
|
placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
|
Eksperimentel: Yogliptin 200mg group
|
Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
|
Eksperimentel: Yogliptin 400mg group
|
Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
HbA1c-ændring fra baseline i uge 24
Tidsramme: Baseline og uge 24
|
Ændring fra baseline i hæmoglobin A1c (HbA1c) i uge 24
|
Baseline og uge 24
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
FPG-ændring fra baseline i uge 24 og uge 52
Tidsramme: Baseline, uge 24 og uge 52
|
Baseline, uge 24 og uge 52
|
2h-PPG Change From Baseline at Week 24 and Week 44 and Week 52
Tidsramme: Baseline, week 24 and Week 44 and Week 52
|
Baseline, week 24 and Week 44 and Week 52
|
Percentage of Patients With HbA1c <6.5%
Tidsramme: Time Frame: Baseline, week 24 and week 52
|
Time Frame: Baseline, week 24 and week 52
|
Procentdel af patienter med HbA1c <7,0 %
Tidsramme: Baseline, uge 24 og uge 52
|
Baseline, uge 24 og uge 52
|
blood pressure Change From Baseline at Week 24 and Week 52
Tidsramme: Baseline, week 24 and week 52
|
Baseline, week 24 and week 52
|
Vægtændring fra baseline i uge 24 og uge 52
Tidsramme: Baseline, uge 24 og uge 52
|
Baseline, uge 24 og uge 52
|
Fasting lipids From Baseline at Week 24 and Week 52
Tidsramme: Baseline, week 24 and week 52
|
Baseline, week 24 and week 52
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Studieleder: Lixin Guo, Beijing Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. januar 2022
Primær færdiggørelse (Forventet)
31. december 2024
Studieafslutning (Forventet)
31. december 2024
Datoer for studieregistrering
Først indsendt
31. marts 2022
Først indsendt, der opfyldte QC-kriterier
31. marts 2022
Først opslået (Faktiske)
8. april 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
20. april 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. april 2022
Sidst verificeret
1. april 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ChengduEastonBiopharma
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkendtHER-2-genamplifikation | HER-2 Protein Overekspression
-
The University of Tennessee, KnoxvilleAfsluttetMatematiklærere (2-8 klassetrin) | Matematikstuderende (2-8 klassetrin)Forenede Stater
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkendtSolid tumor | HER-2-genamplifikation | HER2 genmutation | HER-2 Protein OverekspressionKina
-
PowderMedAfsluttet
-
Argorna Pharmaceuticals Co., LTDAfsluttet
-
Argorna Pharmaceuticals Co., LTDAfsluttet
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Aktiv, ikke rekrutterende
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Aktiv, ikke rekrutterende
-
Arcturus Therapeutics, Inc.Afsluttet
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsAfsluttet
Kliniske forsøg med placebo group
-
Mustafa Kemal UniversityAfsluttet
-
Centro de Atenção ao Assoalho PélvicoIndústria Brasileira Equipamentos Médicos - IBRAMEDRekrutteringErektil dysfunktionBrasilien
-
Universidad Católica San Antonio de MurciaAfsluttetNakke smerter | Triggerpunktssmerter, MyofascialSpanien
-
Arizona Oncology ServicesUkendtLokaliseret brystkræft | Lokaliseret prostatakræft | Patienter, der modtager ekstern strålebehandlingForenede Stater
-
Irmandade Santa Casa de Misericórdia de Porto AlegreUkendtThoraxkirurgiBrasilien
-
University of Sao PauloAfsluttet
-
RenJi HospitalIkke rekrutterer endnuFlydende reaktionsevne | Slagvolumen variation | SVV-FloTrac | Thorax elektrisk bioimpedansKina
-
RenJi HospitalIkke rekrutterer endnuFlydende reaktionsevne | Slagvolumen variation | SVV-FloTrac | Thorax elektrisk bioimpedansKina
-
Ayşegül İşler DalgıçHorizonIkke rekrutterer endnuStress, følelsesmæssig | Sundhedsrisikoadfærd | Sundhedsrelateret adfærd | Sund livsstil | Fysisk inaktivitet | Sund ernæring | Indeks for sund kost | Ikke-smitsomme sygdommeKalkun
-
Boston Medical CenterNational Institute of Mental Health (NIMH)AfsluttetPost traumatisk stress syndromForenede Stater